Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 18 - Number 10
Biography
Review Article
Noxa: Role in Cancer Pathogenesis and Treatment
, 18(10): 914 - 928Rami Z. Morsi, Rouba Hage-Sleiman, Hadile Kobeissy and Ghassan Dbaibo*
DOI: 10.2174/1568009618666180308105048
Review Article
Role of MicroRNAs in Treatment Response in Prostate Cancer
, 18(10): 929 - 944Anshuli Razdan, Paul de Souza* and Tara Laurine Roberts
DOI: 10.2174/1568009618666180315160125
Review Article
PRDM14: A Potential Target for Cancer Therapy
, 18(10): 945 - 956Mengting Ou, Shun Li and Liling Tang*
DOI: 10.2174/1568009618666180430143055
Review Article
Anticancer Properties of Essential Oils: An Overview
, 18(10): 957 - 966Milene Aparecida Andrade, Mariana Aparecida Braga, Pedro Henrique Souza Cesar, Marcus Vinicius Cardoso Trento, Mariana Araújo Espósito, Lucilene Fernandes Silva and Silvana Marcussi*
DOI: 10.2174/1568009618666180102105843
Review Article
Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications
, 18(10): 967 - 978Katarina Kalavska, Vincenza Conteduca, Ugo De Giorgi and Michal Mego*
DOI: 10.2174/1568009618666180102103959
Research Article
Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
, 18(10): 979 - 987Ana Sahores, María May, Gonzalo R. Sequeira, Cynthia Fuentes, Britta Jacobsen, Claudia Lanari and Caroline A. Lamb*
DOI: 10.2174/1568009618666171214114706
Research Article
The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells
, 18(10): 988 - 998Lei Zheng and Jingxuan Pan*
DOI: 10.2174/1568009618666180425142653
Acknowledgement
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Advertisement
Webmaster Contact: info@benthamscience.net